Press Releases

 

Trigemina to Present at the BIO-Europe Spring 2016 Conference

Moraga, Calif. March 29, 2016—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will present at the BIO-Europe Spring 2016 Conference, which will be held in Stockholm, Sweden next week. The presentation will be made by Charles Yeomans, president and chief executive officer […]

Trigemina to Present at the BIO Asia 2016 International Conference

Moraga, Calif. March 9, 2016—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will present at the BIO Asia 2016 International Conference, which will be held in Tokyo, Japan next week. The presentation will be made by Charles Yeomans, president and chief executive […]

Trigemina to Present at Biotech Showcase 2016

Moraga, Calif. January 6, 2016—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will present at the Biotech Showcase 2016 Conference, which will be held in San Francisco, CA next week. The presentation will be made by Charles Yeomans, president and chief executive […]

Trigemina Publishes Data Demonstrating that the Activation of Oxytocin Receptors May Provide Clinical Benefit to Migraine Patients

Moraga, Calif. December 3, 2015—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today the publication of preclinical data demonstrating that the activation of oxytocin receptors in the brain may provide therapeutic benefit in patients with migraine and other primary head pain disorders. The data were published […]

Trigemina to Present at the BIO 14th Annual BIO Investor Forum

Moraga, Calif. October 15, 2015—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that Charles Yeomans, the company’s president and chief executive officer, will present at the BIO 14th Annual BIO Investor Forum in San Francisco next week. The presentation will be webcast and will occur […]

Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer

Moraga, Calif. August 4, 2015—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced today that the company has appointed Shashidhar “Shashi” Kori, M.D., to the position of chief medical officer. Dr. Kori brings over 30 years of clinical development experience to Trigemina, much of which […]

Trigemina Announces Expansion of Phase II Study of TI-001 for Chronic Migraine

MORAGA, CA, Feb. 6, 2014 – Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced it has expanded its Phase II clinical study for TI-001, intranasal oxytocin, beyond Chile to include sites in Brisbane and Adelaide, Australia. “The expansion of the Phase II study […]

Trigemina to Present Migraine Drug Data at Pain Therapeutics Summit East

MORAGA, CA, September 25, 2013 – Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, will be presenting clinical data for its leading drug candidate, TI-001, intranasal oxytocin, for the treatment of chronic migraine at the 7th Annual Pain Therapeutics Summit East, hosted by Arrowhead Publishers, September […]